Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors

Molecular and Cellular Biology

Volumn 16, Issue 12, 1996, Pages 6623-6633

  Adams, Peter D ^a   Sellers, William R ^a   Sharma, Sushil K ^b   Wu, Arthur D ^b   Nalin, Carlo M ^b   Kaelin Jr , William G ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE; CYCLINE; ELONGATION FACTOR 2; ENZYME INHIBITOR; PROTEIN P21; RETINOBLASTOMA PROTEIN; SYNTHETIC PEPTIDE;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0029973557     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.16.12.6623     Document Type: Article

References (94)

1. Ando, K., F. Ajchenbaum-Cymbalista, and J. Griffen. 1993. Regulation of G1/S transition by cyclins D2 and D3 in hematopoitic cells. Proc. Natl. Acad. Sci. USA 90:9571-9575.
2. Baldin, V., J. Lukas, M. J. Marcote, M. Pagano, and G. Draetta. 1993. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:812-821.
3. Bartkova, J., J. Lukas, H. Muller, D. Lutzhoft, M. Strauss, and J. Bartek. 1994. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57:353-361.
4. Bieijersbergen, R. L., E. M. Hijmans, L. Zhu, and R. Bernards. 1994. Interaction of c-myc with the Rb related protein p107 results in inhibition of c-myc mediated transactivation. EMBO J. 13:4080-4086.
5. Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
6. Chen, I.-T., M. Akamatsu, M. L. Smith, F.-D. T. Lung, D. Duba, P. P. Roller, A. J. Fornace, Jr., and P. M. O'Conner. 1996. Characterisation of p21cip1/ waf1 peptide domains required for cyclin E/cdk2 and PCNA interaction. Oncogene 12:595-607.
7. Chen, J., P. K. Jackson, M. W. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature (London) 374:386-388.
8. cip1. Mol. Cell. Biol. In Press.
9. Cobrinik, D., P. Whyte, D. S. Peeper, T. Jacks, and R. A. Weinberg. 1993. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7:2392-2404.
10. Dimri, G., M. Nakanishi, P.-Y. Desprez, J. Smith, and J. Campisi. 1996. Inhibition of E2F activity by the cyclin-dependent kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol. Cell. Biol. 16:2987-2997.
11. Dowdy, S. F., P. W. Hinds, K. Louie, S. I. Reed, A. Arnold, and R. A. Weinberg. 1993. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511.
12. Dynlacht, B. D., O. Flores, J. A. Lees, and E. Harlow. 1994. Differential regulation of E2F transactivation by cyclin/cdk complexes. Genes Dev. 8:1772-1786.
13. Ewen, M. E., B. Faha, E. Harlow, and D. M. Livingston. 1992. Interaction of p107 with cyclin A independent of complex formation with viral oncoproteins. Science 255:85-87.
14. Ewen, M. E., H. K. Sluss, C. J. Sherr, H. Matsushime, J.-Y. Kato, and D. M. Livingston. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497.
15. Ewen, M. E., Y. Xing, J. B. Lawrence, and D. M. Livingston. 1991. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66:1155-1164.
16. Fagan, R., K. J. Flint, and N. Jones. 1994. Phosphorylation of E2F1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19kD protein. Cell 78:799-811.
17. Faha, B., M. Ewen, L. Tsai, D. M. Livingston, and E. Harlow. 1992. Interaction between human cyclin A and adenovirus E1A-associated p107 protein. Science 255:87-90.
18. Fotedar, R., P. Fitzgerald, T. Rouselle, D. Cannella, M. Doree, H. Messier, and A. Fotedar. 1996. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 12: 2155-2164.
19. Frangioni, J., and B. G. Neel. 1993. Solubilisation and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. Anal. Biochem. 210:179-187.
20. Girard, F., U. Strausfeld, A. Fernandez, and N. J. C. Lamb. 1991. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67:1169-1179.
21. Goubin, F., and B. Ducommun. 1995. Identification of binding domains on the p21CIP1 cyclin-dependent kinase inhibitor. Oncogene 10:2281-2287.
22. Gu, W., K. Bhatia, I. T. Magrath, C. V. Dang, and R. Dalla-Favera. 1994. Binding and suppression of the myc transcriptional activation domain by p107. Science 264:251-254.
23. Gu, Y., C. W. Turek, and D. O. Morgan. 1993. Inhibition of cdk2 activity in vivo by an associated 20K regulatory subunit. Nature (London) 366:707-710.
24. Hall, F., R. T. Williams, L. Wu, F. Wu, D. A. Carbonaro-Hall, J. W. Harper, and D. Warburton. 1993. Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein. Oncogene 8:1377-1384.
25. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
26. Hiebert, S. W. 1993. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol. Cell. Biol. 13:3384-3391.
27. Hiebert, S. W., S. P. Chellappan, J. M. Horowitz, and J. R. Nevins. 1992. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 6:177-185.
28. Hinds, P. W., S. Mittnacht, V. Dulic, A. Arnold, S. I. Reed, and R. A. Weinberg. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006.
29. Hoang, A., B. Lutterbach, B. C. Lewis, T. Yano, T. Y. Chou, J. F. Barrett, M. Raffeld, S. R. Hann, and C. V. Dang. 1995 A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-myc transactivation domain. Mol. Cell. Biol. 15:4031-4042.
30. Hunter, T., and J. Pines. 1991. Cyclins and cancer. Cell 66:1071-1074.
31. Hunter, T., and J. Pines. 1994. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582.
32. Kaelin, W. G., Jr., W. Krek, W. R. Sellers, J. A. DeCaprio, F. Ajchenbaum, C. S. Fuchs, T. Chittenden, Y. Li, P. J. Farnham, M. A. Blanar, D. M. Livingston, and E. K. Flemington. 1992. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70:351-364.
33. Kaelin, W. G., Jr., D. C. Pallas, J. A. DeCaprio, F. J. Kaye, and D. M. Livingston. 1991. Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 64:521-532.
34. Kato, J.-Y., and C. J. Sherr. 1993. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc. Natl. Acad. Sci. USA 90:11513-11517.
35. Kato, J.-Y., H. Matsushime, S. W. Hiebert, M. E. Ewen, and C. J. Sherr. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase cdk4. Genes Dev. 7:331-342.
36. Koh, J., G. Enders, B. Dynlacht, and E. Harlow. 1995. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (London) 375:506-510.
37. Krek, W., M. Ewen, S. Shirodkar, Z. Arany, W. G. Kaelin, and D. M. Livingston. 1994. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 78:1-20.
38. Lees, E. 1995. Cyclin dependent kinase regulation. Curr. Opin. Cell Biol. 7:773-780.
39. Lees, E., B. Faha, V. Dulic, S. I. Reed, and E. Harlow. 1992. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev. 6:1874-1885.
40. Lees, J. A., K. J. Buchkovich, D. R. Marshak, C. W. Anderson, and E. Harlow. 1991. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J. 10:4279-4290.
41. Li, Y., C. Graham, S. Lacy, A. M. V. Duncan, and P. Whyte. 1993. The adenovirus E1A-associated 130-kd protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev. 7:2366-2377.
42. Lin, B. T.-Y., S. Gruenwald, A. O. Morla, W.-H. Lee, and J. Y. J. Wang. 1991. Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J. 10:857-864.
43. WAF1 activities. Mol. Cell. Biol. 16:1786-1793.
44. 1 control in retinoblastoma gene deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15:2600-2611.
45. Lukas, J., H. Muller, J. Bartkova, D. Spitkovsky, A. A. Kjerulff, P. Jansen-Durr, M. Strauss, and J. Bartek. 1994. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol. 125:625-638.
46. Lukas, J., D. Parry, L. Aargaard, D. J. Mann, J. Bartkova, M. Strauss, G. Peters, and J. Bartek. 1995. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature (London) 375:503-506.
47. Luo, Y., J. Hurwitz, and J. Massague. 1995. Cell cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature (London) 375:159-161.
48. Marsilio, E., S. H. Cheng, B. Schaffhausen, E. Paucha, and D. M. Livingston. 1991. The T/t common region of simian virus 40 large T antigen contains a distinct transformation-governing sequence. J. Virol. 65:5647-5652.
49. Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuyam, C. J. Sherr, and J.-Y. Kato. 1994. D-type cyclin dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066-2076.
50. 1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 14:2077-2086.
51. Morgan, D. 1995. Principles of CDK regulation. Nature (London) 374:131-134.
52. Muller, H., J. Lukas, A. Schneider, P. Warthoe, J. Bartek, M. Eilers, and M. Strauss. 1994. Cyclin D1 expression is regulated by the retinoblastoma pro-tein. Proc. Natl. Acad. Sci. USA 91:2945-2949.
53. Musgrove, E., C. Lee, M. Buckley, and R. Sutherland. 1994. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA 91:8022-8026.
54. Nakanishi, M., R. S. Robetorye, G. R. Adami, O. M. Pereira-Smith, and J. R. Smith. 1995. Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. EMBO J. 14:555-563.
55. Nigg, E. 1991. The substrates of the cdc2 kinase. Semin. Cell. Biol. 2:261-270.
56. Norbury, C., and P. Nurse. 1992. Animal cell cycles and their control. Annu. Rev. Biochem. 61:441-470.
57. Ohtsubo, M., and J. M. Roberts. 1993. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259:1908-1912.
58. 1/S phase transition. Mol. Cell. Biol. 15:2612-2624.
59. Pagano, M., R. Pepperkok, F. Verde, W. Ansorge, and G. Draetta. 1992. Cyclin A is required at two points in the human cell cycle. EMBO J. 11:961-971.
60. Peeper, D. S., P. Keblusek, K. Helin, M. Toebes, A. J. Van der Eb, and A. Zantema. 1995. Phosphorylation of a specific site in E2F1 affects its electrophoretic mobility and promotes pRb binding in vitro. Oncogene 10:39-48.
61. Peeper, D. S., L. L. Parker, M. E. Ewen, M. Toebes, F. L. Frederick, M. Xu, A. Zantema, A. J. van der Eb, and H. Piwnica-Worms. 1993. A- and B-type cyclins differentially modulate substrate specificity of cyclin-CDK complexes. EMBO J. 12:1947-1954.
62. Polyak, K., M. Lee, H. Erdjument-Bromage, A. Koff, J. M. Roberts, P. Tempst, and J. Massague. 1994. Cloning of p27kip1, a cyclin dependent kinase inhibitor and a potential mediator of extracellular mitogenic signals. Cell 78:59-66.
63. Qin, X.-Q., T. Chittenden, D. M. Livingston, and W. G. Kaelin, Jr. 1992. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6:953-964.
64. Qin, X.-Q., D. M. Livingston, M. E. Ewen, W. R. Sellers, Z. Arany, and W. G. Kaelin, Jr. 1995. The transcription factor E2F1 is a downstream target of RB action. Mol. Biol. Cell. 15:742-755.
65. Quelle, D., R. A. Ashmun, S. A. Shurtleff, J.-Y. Kato, D. Bar-Sagi, M. F. Roussel, and C. J. Sherr. 1993. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 7:1559-1571.
66. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol. 14:1669-1679.
67. Kip1. Mol. Cell. Biol. 15:4347-4352.
68. 1/S transition. Mol. Cell. Biol. 15:3463-3469.
69. Rosenberg, A. R., F. Zindy, F. Le Deist, H. Mouly, P. Metezeau, C. Brechot, and E. Lamas. 1995. Overexpression of human cyclin A advances entry into S phase. Oncogene 10:1501-1509.
70. Russo, A. A., P. D. Jeffrey, A. K. Patten, J. Massague, and N. P. Pavletich. 1996. Crystal structure of the p27kip1 cyclin dependent kinase inhibitor bound to the cyclin A-cdk2 complex. Nature (London) 382:325-331.
71. Sellers, W. R., and W. G. Kaelin, Jr. Unpublished data.
72. Sherr, C. J., and J. M. Roberts. 1995. Inhibitors of mammalian G1 cyclin dependent kinases. Genes Dev. 9:1149-1163.
73. Shirodkar, S., M. Ewen, J. A. DeCaprio, J. Morgan, D. M. Livingston, and T. Chittenden. 1992. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 68:157-166.
74. Shiyanov, P., S. Bagchi, G. Adami, J. Kokontis, N. Hay, M. Arroyo, A. Morozov, and P. Raychaudhuri. 1996. p21 disrupts the interaction between cdk2 and the E2F-p130 complex. Mol. Cell. Biol. 16:737-744.
75. Smith, E. J., and J. R. Nevins. 1995. The Rb related p107 protein can suppress E2F function independently of binding to cyclin A/cdk2. Mol. Cell. Biol. 15:338-344.
76. Songyang, Z., S. Blechner, N. Hoagland, M. F. Hoekstra, H. Piwnica-Worms, and L. C. Cantley. 1994. Use of an orientated peptide library to determine the optimal substrates of protein kinases. Curr. Biol. 4:973-982.
77. Srinivasan, J., M. Koszelak, M. Mendelow, Y.-G. Kwon, and D. S. Lawrence. 1995. The design of peptide based substrates for the cdc2 protein kinase. Biochem. J. 309:927-931.
78. Su, J. Y., R. E. Rempel, E. Erikson, and J. L. Maller. 1995. Cloning and characterisation of the Xenopus cyclin-dependent kinase inhibitor p27 XIC1. Proc. Natl. Acad. Sci. USA 92:10187-10191.
79. Toyoshima, H., and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin/cdk protein kinase activity is related to p21. Cell 78:67-74.
80. Vairo, G., D. M. Livingston, and D. Ginsberg. 1995. Functional interaction between E2F4 and p130: evidence for distinct mechanisms underlying growth suppression by different Rb family members. Genes Dev. 9:869-881.
81. Van den Heuvel, S., and E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262:2050-2053.
82. Warbrick, E., D. P. Lane, D. M. Glover, and L. S. Cox. 1995. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and the proliferating cell nuclear antigen. Curr. Biol. 5:275-282.
83. Williams, R. T., D. A. Carbonaro-Hall, and F. L. Hall. 1992. Co-purification of p34 cdc2/p58cyclin A proline-directed protein kinase and the retinoblastoma tumor susceptibility gene product: interaction of an oncogenic serine-threonine protein kinase with a tumor-suppressor protein. Oncogene 7:423-432.
84. Wilson, I. A., D. H. Haft, E. D. Getzoff, J. A. Tainer, R. A. Lerner, and S. Brenner. 1985. Identical short peptide sequences in unrelated proteins can have different confirmations: a testing groud for theories of immune recognition. Proc. Natl. Acad. Sci. USA 82:5255-5259.
85. Wimmel, A., F. C. Lucibello, A. Sewing, S. Adolph, and R. Muller. 1994. Inducible acceleration of G1 progression through tetracycline-regulated expression of human cyclin E. Oncogene 9:995-997.
86. Xiong, Y., G. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature (London) 366: 701-704.
87. Xiong, Y., H. Zhang, and D. Beach. 1993. Subunit rearrangement of the cyclin dependent kinases is associated with cellular transformation. Genes Dev. 7:1572-1583.
88. Xu, M., K. A. Sheppard, C.-Y. Peng, A. S. Yee, and H. Piwnica-Worms. 1994. Cyclin A/cdk2 binds directly to E2F1 and inhibits the DNA-binding activity of E2F1/DP1 by phosphorylation. Mol. Cell. Biol. 14:8420-8431.
89. Zhang, H., G. J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1750-1758.
90. Zhang, J., R. J. Sanchez, S. Wang, C. Guarnaccia, A. Tossi, S. Zahariev, and S. Pongor. 1994. Substrate specificity of cdc2 kinase from human HeLa cells as determined with synthetic peptides and molecular modelling. Arch. Biochem. Biophys. 315:415-424.
91. Zhu, L., G. Enders, J. A. Lees, R. L. Beijersbergen, R. Bernards, and E. Harlow. 1995. The pRB-related protein p107 contains two growth suppression domains: independent interactions with E2F and cyclin/cdk complexes. EMBO J. 14:1904-1913.
92. Zhu, L., E. Harlow, and B. D. Dynlacht. 1995. p107 uses a p21/CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev. 9:1740-1752.
93. Zhu, L., S. van der Heuvel, K. Helin, A. Fattaey, M. Ewen, D. M. Livingston, N. Dyson, and E. Harlow. 1993. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev. 7:1111-1125.
94. Zindy, F., E. Lamas, X. Chenivesse, J. Sobczak, J. Wang, D. Fesquet, B. Henglein, and C. Brechot. 1992. Cyclin A is required in S phase in normal epithelial cells. Biochem. Biophys. Res. Commun. 182:1144-1154.